Clinical trials demonstrate that JYNNEOS is well-tolerated with similar immunogenicity and rates of adverse events in persons with HIV infection with CD4 cell counts of 200–750 per μL and persons without HIV infection (25,26). This evidence concerns the gene CD4 and HIV infectious disease.